Following the PharmaCo spin-off, Daniel Rosenbaum, current CEO of NattoPharma will be seconded to PharmaCo in order to assure an effective transition and
immediate start-up of PharmaCo critical operations. Of equal importance is for NattoPharma to continue with its growth and performance gains. Thus, during this period, the Board of Directors of NattoPharma has further appointed Kjetil Ramsøy, current NattoPharma CFO, as Interim CEO. Mr. Ramsøy will also continue to act as CFO during this
period. In line with this priority, Mr. Peter Stahl, an expert in the areas of operations management, has joined the NattoPharma team for an extended engagement as Interim COO.